SEC Comment Letter for Beyond Air, Inc. (XAIR) (CIK 0001641631) (XAIR) — May 23, 2019
Beyond Air, Inc. (XAIR) (CIK 0001641631)
Date: May 23, 2019 · CIK: 0001641631 · Accession: 0000000000-19-008880
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-231416
Letter
May 23, 2019 Steven Lisi Chairman & Chief Executive Officer AIT Therapeutics, Inc. 825 East Gate Blvd., Suite 320 Garden City, New York 11530 Re:AIT Therapeutics, Inc. Registration Statement on Form S-3 Filed May 13, 2019 File No. 333-231416 Dear Mr. Lisi: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Michael Fay at 202-551-3812 with any questions. Sincerely, Division of Corporation Finance Office of Electronics and Machinery cc: Avital Perlman, Esq.
Show Raw Text
May 23, 2019
Steven Lisi
Chairman & Chief Executive Officer
AIT Therapeutics, Inc.
825 East Gate Blvd., Suite 320
Garden City, New York 11530
Re:AIT Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 13, 2019
File No. 333-231416
Dear Mr. Lisi:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Michael Fay at 202-551-3812 with any questions.
Sincerely,
Division of Corporation Finance
Office of Electronics and Machinery
cc: Avital Perlman, Esq.